PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.\', \'Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.\', \'Department of Nursing, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan.\', \'Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.\', \'Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.\', \'Central Research Laboratories, Sysmex Corporation, Hyogo, Japan.\', \'Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1001/jamaoncol.2021.2159
?:hasPublicationType
?:journal
  • JAMA oncology
is ?:pmid of
?:pmid
?:pmid
  • 34047762
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.187
?:rankingScore_hIndex
  • 41
is ?:relation_isRelatedTo_publication of
?:title
  • Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all